As an inhibitory Notch ligand, DLL3 expression exhibits a positive correlation with survival outcomes in mIDH1 gliomas (35), Glioma cases with elevated DLL3 levels demonstrate enhanced immune cell infiltration, suggesting a functional link between Notch pathway activation and immune responsiveness in these neoplasms. Here, DLL3 is linked to central nervous system cancer.